-
2023-504013-68-00
1
2024-09-06
Advanced or Metastatic Prostate Cancer
-
2024-511074-80-01
7
2024-09-06
Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refrac
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2023-505616-38-00
4
2024-09-04
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
-
2023-504647-14-00
4
2024-09-02
Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-506617-21-00
5
2024-08-29
Major depressive disorder
-
2023-509687-14-00
1
2024-08-29
Advanced solid tumors
-
2023-507692-21-00
3
2024-08-22
Bullous pemphigoid
-
2022-502757-34-00
1
2024-08-20
Advanced solid tumors
-
2023-503859-10-00
5
2024-08-12
Moderate to Severe Plaque Psoriasis
-
2023-508435-31-00
1
2024-08-09
Advanced Solid Tumors, Advanced Breast Cancer
-
2024-512742-42-00
4
2024-08-09
Pancreatic carcinoma
-
2023-503550-13-00
7
2024-08-08
Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
-
2023-507809-34-00
9
2024-08-07
Relapsed or Refractory Systemic Light Chain Amyloidosis
-
2023-509532-25-00
1
2024-08-07
Solid tumor
-
2023-506199-28-00
1
2024-08-05
Dose escalation: Advanced Solid Tumors
Dose Expansion: Squamous non-sm
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-508703-21-00
9
2024-08-01
Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), bili
-
2023-504169-22-02
5
2024-07-31
Severe cardiac inflammation
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2023-504898-20-00
4
2024-07-30
Thyroid neoplasms:
● Cohort 1: Advanced radioactive-iodine refractory
-
2024-512175-12-00
1
2024-07-29
Low tumour volume (LTV) advanced, metastatic, or recurrent solid malig
-
2023-510173-34-00
5
2024-07-26
Relapsed/refractory multiple myeloma